726 related articles for article (PubMed ID: 31482678)
1. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
3. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
5. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Thorac Cancer; 2019 Dec; 10(12):2259-2266. PubMed ID: 31679185
[TBL] [Abstract][Full Text] [Related]
6. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
7. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
9. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
13. Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
Wang X; Zhao J; Mei T; Liu W; Chen X; Wang J; Jiang R; Ye Z; Huang D
BMC Cancer; 2024 Feb; 24(1):269. PubMed ID: 38408928
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
Front Immunol; 2021; 12():818492. PubMed ID: 35095920
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
[No Abstract] [Full Text] [Related]
16. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
[TBL] [Abstract][Full Text] [Related]
18. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
19. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
Harada D; Takata K; Mori S; Kozuki T; Takechi Y; Moriki S; Asakura Y; Ohno T; Nogami N
Anticancer Res; 2019 Sep; 39(9):4987-4993. PubMed ID: 31519605
[TBL] [Abstract][Full Text] [Related]
20. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
